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Background: Hepatic angiomyolipoma is a rare benign mesenchymal tumor. We report an unusual case of a
patient with multiple hepatic angiomyolipomas exhibiting high 18 F-fluorodeoxyglucose (FDG) uptake.
Case presentation: A 29-year-old man with a medical history of tuberous sclerosis was admitted to our hospital for
fever, vomiting, and weight loss. Abdominal dynamic computed tomography revealed faint hypervascular hepatic
tumors in segments 5 (67 mm) and 6 (10 mm), with rapid washout and clear borders; however, the tumors exhibited
no definite fatty density. Abdominal magnetic resonance imaging revealed that the hepatic lesions were slightly
hypointense on T1-weighted imaging, slightly hyperintense on T2-weighted imaging, and hyperintense with no
apparent fat component on diffusion-weighted imaging. FDG-positron emission tomography (PET) imaging revealed
high maximum standardized uptake values (SUVmax) of 6.27 (Segment 5) and 3.22 (Segment 6) in the hepatic
tumors. A right hepatic lobectomy was performed, and part of the middle hepatic vein was also excised. Histological
examination revealed that these tumors were characterized by the background infiltration of numerous inflammatory
cells, including spindle-shaped cells, and a resemblance to an inflammatory pseudotumor. Immunohistochemical
evaluation revealed that the tumor stained positively for human melanoma black-45. The tumor was therefore considered
an inflammatory pseudotumor-like angiomyolipoma. Although several case reports of hepatic angiomyolipoma
have been described or reviewed in the literature, only 3 have exhibited high 18 F-FDG uptake on PET imaging
with SUVmax ranging from 3.3–4.0. In this case, increased 18 F-FDG uptake is more likely to appear, particularly if
the inflammation is predominant.
Conclusion: Although literature regarding the role of 18 F-FDG-PET in hepatic angiomyolipoma diagnosis is limited
and the diagnostic value of 18 F-FDG-PET has not yet been clearly defined, the possibility that hepatic angiomyolipoma
might exhibit high 18 F-FDG uptake should be considered.
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Angiomyolipoma (AML) of the liver is a rare benign
mesenchymal tumor with positive human melanoma
black-45 (HMB-45) expression and a heterogeneous com-
position of blood vessels, and smooth muscle cells, and
adipose tissue cells, which account for the tumors varying
morphological features [1]. Most AMLs contain various
amount of fat that enable detection via computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) [2-5].
However, some hepatic AMLs have low fat contents, pos-
ing difficulties for establishing a definitive preoperative* Correspondence: gunma_radtech@yahoo.co.jp
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unless otherwise stated.diagnosis [6,7]. Diagnostic functional positron emission
tomography (PET) imaging using an 18 F-fluorodeoxyglu-
cose (FDG) tracer is a useful technique for detecting and
differentiating benign and malignant tumors. Similar to
benign tumors, which tend to exhibit low FDG uptake,
hepatic AMLs have been reported to exhibit similarly low
uptake levels in the absence of hemorrhage [8]. However,
we encountered a distinct case with multiple AMLs with
high FDG uptake in the liver of a 29-year-old man.
Case presentation
A 29-year-old man with a medical history of tuberous
sclerosis was admitted to our hospital for fever, vomit-
ing, and weight loss (4 kg/month). His serum C-reactive
protein and hepatic enzyme levels were increased. Testsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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such as alpha-fetoprotein, carcinoembryonic antigen, pro-
tein induced by vitamin K absence-2, and cancer antigen
19–9 were negative.
Abdominal dynamic CT revealed faint hypervascular
hepatic tumors in segments 5 (S5; 67 mm) and 6 (S6;
10 mm), with rapid washout and clear borders but with-
out definite fatty densities. CT also revealed multiple
tumors with fat components in both kidneys, but these
did not show definite enhancements (Figure 1).
Abdominal MR imaging (1.5 T Magnetom Symphony;
Siemens Medical Solutions, Erlangen, Germany) revealed
that the hepatic lesions were slightly hypointense on
T1-weighted imaging (T1WI), slightly hyperintense on
T2-weighted imaging (T2WI), and hyperintense on
diffusion-weighted imaging (DWI) with no apparent fat
component (Figure 2). The tumors in both kidneys
were mildly hypointense on both T1WI and T2WI and
mildly hyperintense with fat components on DWI.
18 F-FDG PET/CT (Biograph 16; Siemens Medical Solu-
tions, Erlangen, Germany) imaging revealed that the
hepatic tumors exhibited high maximum standard uptake
values (SUVmax) of 6.27 (S5) and 3.22 (S6; Figure 3). No
definite FDG-uptake was observed in the renal AMLs.Figure 1 Abdominal computed tomography. (A) Axial computed tomo
(B) On early-phase axial contrast-enhanced CT imaging, the lesion exhibits he
CT imaging, the lesion shows rapid washout in segment 5. (D) The segmentAlthough a preoperative percutaneous biopsy was per-
formed and a histological examination of the specimens
suggested the diagnosis of angiomyolipoma, the high
FDG uptake and increasing tumor sizes made it difficult
to exclude a malignant transformation of angiomyoli-
poma. A right hepatic lobectomy was performed and a
part of the middle hepatic vein was also excised. The pa-
tient recovered well after surgery. His initial symptoms
resolved completely, and his serological parameters of
inflammation returned to normal by the time of release
from hospital. Currently, the patient remains in a healthy
condition and has exhibited no signs of recurrence at
4 years after surgery.
Histological examination revealed that these tumors were
characterized by the background infiltration of numerous
inflammatory cells, including spindle-shaped cells, and an
absence of fat (Figure 4) and thus resembled inflammatory
pseudotumors. On immunohistochemical analysis, the
tumors stained positively for HMB-45, CD31, vimentin,
and α-smooth muscle actin. However, the tumor cells
were negative for keratin, epithelial membrane antigen,
hepatocyte paraffin1, c-kit, CD34, CD56, and S-100.
The tumor was hence diagnosed as an inflammatory
pseudotumor-like AML.graphy (CT) imaging shows a liver lesion (arrow) with low attenuation.
terogeneous enhancement. (C) On portal-phase axial contrast-enhanced
6 lesion exhibits a similar pattern (arrowhead).
Figure 2 Abdominal magnetic resonance (MR) imaging. Abdominal magnetic resonance (MR) imaging revealed that the hepatic tumors
(segment 5: arrow, segment 6: arrowhead) were slightly hypointense on T1-weighted imaging (WI), slightly hyperintense on T2WI, and hyperintense
without an apparent fat component on diffusion-weighted imaging.
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AML is a benign mesenchymal tumor that has reportedly
occurred frequently in the kidney but rarely in the liver.
Approximately 5%–10% of hepatic AML are associated
with renal AML and tuberous sclerosis (Bourneville’s
disease), and this was true for our patient. The first
case of hepatic AML was described by Ishak in 1976
[9]. Although fatty tissue is a characteristic of AML, the
fat content within the tumor can range from 5% to 90% of
the tumor volume, thus resulting in varying radiological
appearances [2,5,6,10]. Preoperative diagnosis relies on
imaging studies, which include CT and MRI. However,
it is often difficult to distinguish these lesions from
other hepatic fatty tumors such as fat-containing hep-
atic adenomas or hepatocellular carcinomas with fatty
metamorphosis.Figure 3 18F-fluorodeoxyglucose (FDG) positron emission tomograph
angiomyolipomas. The fused PET/CT image demonstrates the markedly inAlthough AMLs are considered benign, malignant
transformation is not a rare complication associated
with renal AML [11]. In recent years, the malignant
transformation of hepatic AML has also been reported
in the literature [12,13]. 18 F-FDG PET/CT is useful for
detecting malignant transformation [14]. Moreover, be-
cause hepatic AML has been reported to exhibit low 18
F-FDG-uptake [8], 18 F-FDG PET/CT might be highly
valuable for excluding malignancies among hepatic
lesions suspected to be AML.
We performed a Medline search using the search
terms “liver”, “angiomyolipoma”, and “FDG”. Although
several case reports of hepatic AML have been described
or reviewed in the literature, only 3 cases exhibited high
18 F-FDG uptake on PET imaging, with SUVmax ranging
from 3.3–4.0 [8,13,15-20] (Table 1).y (PET)/computed tomography (CT) imaging of hepatic
creased FDG uptake in segments 5 and 6 of the liver.
Figure 4 Histological features of hepatic angiomyolipomas. (A, B) Histological examination revealed the background infiltration of numerous
inflammatory cells, including spindle-shaped cells (A: original magnification = 20×, scale bar = 50 μm, B: 40×, scale bar = 100 μm; hematoxylin–eosin
staining). (C) The immunohistochemical analysis revealed positive staining for human melanoma black-45 (HMB-45; original magnification = 20×, scale
bar = 50 μm). (D) In a gross examination, the cut AML surfaces revealed well-delineated borders and slightly variegated appearances.
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tabolism in smooth muscle cells and a high cell density
due to the lack of a fat component might increase the
18 F-FDG uptake. Takanami et al. [8] suggested that
hepatic AMLs might exhibit increased 18 F-FDG uptake
in the presence of hemorrhage or an inflammatory
response. In such cases, increased 18 F-FDG uptake is
more likely to appear, particularly if the inflammatory
tissue is predominant. Because the average mean SUV
of the normal liver is approximately 3.5 ± 3.1 and the
malignant lesion-to-liver SUV ratio is approximately
1.9 ± 1.4 [21], the FDG uptakes of the angiolipomas
described in Table 1 were easily obscured by the FDGTable 1 Reports of FDG uptake in hepatic AMLs to the
present date
Author Age Gender Tumor size (cm) SUVmax
Takanami [8] 74 Female 20 Low
62 Female 15 4.0
Awane [15] 48 Female 6 Low
Kubo [16] 70 Female 3.2 1.9
Kinugasa [17] 42 Female 1.4 3.9
Sakaguchi [18] 80 Female 4.3 3.3
Kawaoka [19] 41 Female 3.9 1.9
Lhommel R [20] 64 - 7 Low
Lee JH [6] 47 Female 4 Low
FDG, 18 F-fluorodeoxyglucose; AML, angiomyolipoma; SUVmax, maximum
standard uptake value.uptake of the normal liver tissue. In our case, the
angiolipomas exhibited apparently high levels of FDG
uptake.
Recently, some hepatic epithelioid AMLs have been
reported to have features similar to those of renal AMLs
reported previously. Epithelioid AMLs either lack or
contain only a minimal amount of adipose tissue and
are thus more difficult to distinguish from other hyper-
vascular tumors. The imaging features of epithelioid
AMLs include an absent capsule and hypervascularity
with central punctiform or filiform vessels that exhibit
characteristic enhancement [22,23]. No literature reports
have described the FDG-PET imaging features of epi-
thelioid AMLs. In our case, although the CT and MRI
imaging features were similar to those of epithelioid AML,
no epithelial cells were observed in a histopathological
examination.
The presence of HMB-45-positive smooth muscle cells
in an immunostaining analysis is the definitive criterion
for diagnosing hepatic AML [24]. Although AML was
already suggested by the findings the preoperative percu-
taneous biopsy, we could not completely rule out the
possibility of malignancy because of the atypical MRI
findings and high 18 F-FDG uptake in the lesions.
Conclusion
We report herein a case of multiple hepatic angiomyoli-
pomas with high 18 F-FDG uptake. Although the litera-
ture reports on the role of 18 F-FDG PET/CT in hepatic
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http://www.biomedcentral.com/1471-2342/14/17AML diagnosis are limited and the diagnostic value of
18 F-FDG PET/CT has not yet been clearly defined,
the possibility that hepatic AML might exhibit high
18 F-FDG uptake should be considered.
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